| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | SOPHIRIS BIO INC | 200,000 | 560,000 | 0.32% | ||
| 2 | INNOCOLL HLDGS PLC | 2,103,173 | 1,451,000 | 0.82% | ||
| 3 | HISTOGENICS CORP | 2,077,040 | 3,469,000 | 1.95% | ||
| 4 | Mirna Therapeutics, Inc. | 2,974,812 | 5,355,000 | 3.01% | ||
| 5 | AURIS MED HLDG AG | 5,818,175 | 6,225,000 | 3.50% | ||
| 6 | Natera, Inc. | 1,550,280 | 18,154,000 | 10.22% | ||
| 7 | VERSARTIS INC | 2,361,978 | 35,193,000 | 19.80% | ||
| 8 | SPARK THERAPEUTICS INCORPORATED | 904,986 | 45,159,000 | 25.41% | ||
| 9 | ACLARIS THERAPEUTICS INC COM | 2,289,480 | 62,136,000 | 34.97% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0001144204-17-008464, filed 2017.02.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
